Clinical Trials

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06317649 2026-04-17

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

147 enrolled

Leukemia, Myeloid, Acute

NCT04140487 2026-04-16

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

97 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05756777 2026-03-27

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

18 enrolled

Leukemia, Myeloid, Acute

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07463651 2026-03-20

TROPHY-15

Phase 3 Recruiting

594 enrolled

Leukemia, Myeloid, Acute

NCT06222580 2026-03-13

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

30 enrolled

Leukemia, Myeloid, Acute

NCT04293562 2026-02-24

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3 Recruiting

1,186 enrolled

Leukemia, Myeloid, Acute

NCT05010122 2026-02-18

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

42 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

125 enrolled

Leukemia, Myeloid, Acute

NCT06235801 2025-11-19

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

20 enrolled

Leukemia, Myeloid

NCT02115295 2025-11-06

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

508 enrolled

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06696183 2025-05-29

SEQUENCE

60 enrolled

Leukemia, Myeloid, Acute

NCT06022003 2025-03-24

OGILAR

33 enrolled

Leukemia, Myeloid, Acute

NCT06221683 2024-08-22

GMCAII

500 enrolled

Leukemia, Myeloid, Acute

NCT05546580 2024-07-29

FRIDA

50 enrolled